Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CDC73_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CDC73_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CDC73_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CDC73_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CDC73_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CDC73_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CDC73_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000651321 | Oral cavity | EOLP | protein monoubiquitination | 17/2218 | 67/18723 | 1.68e-03 | 1.11e-02 | 17 |
GO:200004521 | Oral cavity | EOLP | regulation of G1/S transition of mitotic cell cycle | 29/2218 | 142/18723 | 2.27e-03 | 1.41e-02 | 29 |
GO:007122222 | Oral cavity | EOLP | cellular response to lipopolysaccharide | 39/2218 | 209/18723 | 2.62e-03 | 1.58e-02 | 39 |
GO:003278612 | Oral cavity | EOLP | positive regulation of DNA-templated transcription, elongation | 9/2218 | 27/18723 | 2.88e-03 | 1.70e-02 | 9 |
GO:003424321 | Oral cavity | EOLP | regulation of transcription elongation from RNA polymerase II promoter | 10/2218 | 32/18723 | 2.93e-03 | 1.72e-02 | 10 |
GO:000170611 | Oral cavity | EOLP | endoderm formation | 14/2218 | 54/18723 | 3.37e-03 | 1.94e-02 | 14 |
GO:00456382 | Oral cavity | EOLP | negative regulation of myeloid cell differentiation | 20/2218 | 90/18723 | 3.81e-03 | 2.11e-02 | 20 |
GO:000636821 | Oral cavity | EOLP | transcription elongation from RNA polymerase II promoter | 16/2218 | 69/18723 | 5.92e-03 | 2.98e-02 | 16 |
GO:0048147 | Oral cavity | EOLP | negative regulation of fibroblast proliferation | 9/2218 | 30/18723 | 6.33e-03 | 3.13e-02 | 9 |
GO:007121914 | Oral cavity | EOLP | cellular response to molecule of bacterial origin | 39/2218 | 221/18723 | 6.97e-03 | 3.39e-02 | 39 |
GO:000170412 | Oral cavity | EOLP | formation of primary germ layer | 24/2218 | 121/18723 | 7.53e-03 | 3.62e-02 | 24 |
GO:005067816 | Oral cavity | EOLP | regulation of epithelial cell proliferation | 61/2218 | 381/18723 | 8.75e-03 | 4.06e-02 | 61 |
GO:00335231 | Oral cavity | EOLP | histone H2B ubiquitination | 5/2218 | 12/18723 | 8.97e-03 | 4.12e-02 | 5 |
GO:190331133 | Oral cavity | NEOLP | regulation of mRNA metabolic process | 91/2005 | 288/18723 | 2.65e-22 | 7.88e-19 | 91 |
GO:005068433 | Oral cavity | NEOLP | regulation of mRNA processing | 56/2005 | 137/18723 | 4.37e-20 | 6.48e-17 | 56 |
GO:003164733 | Oral cavity | NEOLP | regulation of protein stability | 73/2005 | 298/18723 | 7.46e-12 | 1.17e-09 | 73 |
GO:007182634 | Oral cavity | NEOLP | ribonucleoprotein complex subunit organization | 60/2005 | 227/18723 | 1.98e-11 | 2.81e-09 | 60 |
GO:001605532 | Oral cavity | NEOLP | Wnt signaling pathway | 93/2005 | 444/18723 | 1.35e-10 | 1.34e-08 | 93 |
GO:002261834 | Oral cavity | NEOLP | ribonucleoprotein complex assembly | 57/2005 | 220/18723 | 1.46e-10 | 1.43e-08 | 57 |
GO:019873832 | Oral cavity | NEOLP | cell-cell signaling by wnt | 93/2005 | 446/18723 | 1.73e-10 | 1.66e-08 | 93 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDC73 | SNV | Missense_Mutation | | c.1073G>A | p.Arg358Gln | p.R358Q | Q6P1J9 | protein_coding | deleterious(0.01) | probably_damaging(0.949) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CDC73 | SNV | Missense_Mutation | | c.1352N>T | p.Ala451Val | p.A451V | Q6P1J9 | protein_coding | tolerated(0.06) | benign(0.119) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CDC73 | SNV | Missense_Mutation | | c.1019N>C | p.Val340Ala | p.V340A | Q6P1J9 | protein_coding | tolerated(0.78) | benign(0.007) | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CDC73 | SNV | Missense_Mutation | novel | c.1034N>A | p.Ser345Tyr | p.S345Y | Q6P1J9 | protein_coding | tolerated(0.13) | probably_damaging(0.949) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
CDC73 | SNV | Missense_Mutation | novel | c.947N>T | p.His316Leu | p.H316L | Q6P1J9 | protein_coding | deleterious(0.01) | probably_damaging(0.986) | TCGA-AR-A2LN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
CDC73 | SNV | Missense_Mutation | | c.1247N>A | p.Gly416Asp | p.G416D | Q6P1J9 | protein_coding | deleterious(0.03) | benign(0.03) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
CDC73 | SNV | Missense_Mutation | novel | c.1537N>T | p.Arg513Trp | p.R513W | Q6P1J9 | protein_coding | deleterious(0.02) | possibly_damaging(0.562) | TCGA-BH-A5IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
CDC73 | SNV | Missense_Mutation | novel | c.72N>C | p.Glu24Asp | p.E24D | Q6P1J9 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-S3-AA17-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
CDC73 | SNV | Missense_Mutation | | c.921N>G | p.Phe307Leu | p.F307L | Q6P1J9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
CDC73 | SNV | Missense_Mutation | rs878855091 | c.787C>T | p.Arg263Cys | p.R263C | Q6P1J9 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |